Drug Profile
Zegocractin - CalciMedica
Alternative Names: Auxora; CM-4620; CM4620-IELatest Information Update: 18 Mar 2024
Price :
$50
*
At a glance
- Originator CalciMedica
- Class Anti-inflammatories; Antivirals; Benzamides; Chlorobenzenes; Dioxoles; Fluorobenzenes; Pyrazines; Small molecules
- Mechanism of Action Immunosuppressants; ORAI1 protein inhibitors; STIM1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III COVID-19 pneumonia
- Phase II Pancreatitis; SARS-CoV-2 acute respiratory disease; Systemic inflammatory response syndrome
- Preclinical Acute kidney injury; Inflammatory bowel diseases; Renal failure; Respiratory distress syndrome
Most Recent Events
- 13 Mar 2024 Pharmacodynamics data from preclinical studies in Acute kidney injury released by CalciMedica
- 28 Feb 2024 Preclinical trials in Acute kidney injury in USA (IV) prior to February 2024
- 28 Feb 2024 Pharmacodynamics data from a preclinical studies in Acute kidney injury released by CalciMedica